Search results: (10000)
News Prognostic Significance of Mutations in Maintenance Hypomethylation Therapy for AML Patients
A recently published sub-analysis of the QUAZAR AML-001 clinical trial evaluated the efficacy of maintenance treatment for acute myeloid leukemia (AML) with oral azacitidine, considering the initial mutational status of NPM1 and FLT3 genes and the presence of minimal residual disease (MRD) in patients after the completion of intensive chemotherapy.
News Study TACTIC – Efficacy and Safety of Trifluridine/Tipiracil in Pre-treated mCRC Patients in Real-world Practice
In the pivotal phase III RECOURSE randomized placebo-controlled study, therapy with trifluridine/tipiracil (FTD/TPI) was associated with improved overall survival and progression-free survival in pre-treated metastatic colorectal cancer (mCRC) patients. The below-presented TACTIC study provides prospective data from German real-world practice.
News Vaccination and ALEmtuzumab: ALE when?
When, why and against what should patients with multiple sclerosis treated with alemtuzumab be vaccinated? And is vaccination effective in this population?
News Prediction of Hypocalcemia Risk in Patients Treated with Denosumab and Active Form of Vitamin D
According to new work by Japanese authors, it appears that the risk factors for the development of hypocalcemia in patients treated with denosumab and calcitriol (the active form of vitamin D) are different from those when natural vitamin D is added to denosumab.
News Current Expert Consensus on Prophylaxis of Individuals with Mild and Moderate Hemophilia A: These Patients Also Deserve Better Care
What is the importance of prophylaxis in 'non-severe' hemophilia A? Italian doctors have attempted to answer this question in their recent expert consensus.
News EULAR 2023: How does tofacitinib affect cardiovascular risk in rheumatoid arthritis?
At this year's European League Against Rheumatism (EULAR) congress, held at the turn of May and June in Milan, Italy, a study was presented that examined the impact of tofacitinib use on cardiovascular (CV) risk in patients with active rheumatoid arthritis (RA).
News DPP-4 Inhibitors May Prevent SARS-CoV-2 Entry into Cells
Since the new type of coronavirus SARS-CoV-2 utilizes the DPP-4 receptor to enter human cells, DPP-4 inhibition by gliptins could represent a potential approach to pharmacological treatment of COVID-19 caused by this coronavirus.
News Does Tofacitinib Improve Comorbid Depressive and/or Anxiety Symptoms in Patients with Rheumatoid Arthritis?
Depression and anxiety disorders are commonly observed in patients with rheumatoid arthritis and can lead to a reduction in quality of life, functional capacity, and, last but not least, to a lower therapeutic response. Therefore, the study presented below examined the prevalence of depressive and generalized anxiety disorders in clinical trials using tofacitinib and the effectiveness of tofacitinib according to baseline values of depression and anxiety.
News Efficacy of Reduced Dose Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis
The introduction of tumor necrosis factor inhibitors marked a breakthrough in the treatment of axial spondyloarthritis and other autoimmune diseases. One disadvantage of using these drugs can be increased susceptibility of patients to various infectious agents. The aim of the presented meta-analysis was therefore to determine whether a reduced dose of TNF inhibitors provides the same efficacy with a more favorable safety profile compared to the standard dosing regimen.
News Shared Decision Making Plays an Important Role in Dialysis
Peritoneal dialysis is very effective and comfortable for patients, yet it is used relatively little in the Czech Republic. Are we giving enough room to patients' preferences?
News Safety of Dabigatran in the Secondary Prevention of Venous Thromboembolism in Children
The direct thrombin inhibitor dabigatran is used by adult patients, among others, in the secondary prevention of venous thromboembolism (VTE). Its safety in the pediatric population was the focus of the international phase III study presented below.
News Observational Study of Pegylated rVIII Administration in Real Clinical Practice
A recently published article by American hematologists provided valuable information about the treatment with pegylated recombinant factor VIII (rVIII) in real clinical practice. This is the most extensive observational study to date that evaluates the clinical effect of the treatment and at the same time compares the consumption of FVIII in people with hemophilia A who have changed medication from normal half-life (SHL) or extended half-life (EHL) concentrates to pegylated rVIII.
News Cost-effectiveness in Bleeding Control for Acquired Hemophilia A
A pharmacoeconomic analysis showed favorable cost-effectiveness of activated prothrombin complex concentrate in the indication of bleeding control in patients with acquired hemophilia A.
News Dupilumab in the Treatment of Severe Asthma in Real-World Practice
A freshly published French study is the first to confirm the results of clinical trials with dupilumab in patients with severe asthma in real-world practice.
News Reflection of Progress in Hemophilia Treatment in Current WFH Recommendations
In June 2020, the new, third guidelines of the World Federation of Hemophilia (WFH) were introduced. They are based on the fact that in the past 5 years there has been significant progress in the management of hemophilia, mainly due to the introduction of new − even revolutionary − drugs into clinical practice.
News Remarkable Findings from the Subanalysis of the Efficacy and Safety of Teriflunomide in the Chinese Population with MS in Relation to Global Results
Teriflunomide, from the group of disease-modifying drugs (DMDs), intended for the treatment of patients with multiple sclerosis (MS), inhibits the proliferation of lymphocytes. As a result, fewer lymphocytes that could damage the CNS pass through the blood-brain barrier. The efficacy and safety of teriflunomide in the global population were examined in the multinational randomized double-blind placebo-controlled TOWER study, with an interesting subanalysis published by Chinese authors.
News Cost Effectiveness of Netupitant/Palonosetron Combination in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting
A recently published study compared the costs of achieving a complete response to antiemetic therapy in the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) when using a combination of netupitant and palonosetron (NEPA) versus palonosetron alone, both administered with dexamethasone. The results showed significantly better cost-effectiveness for NEPA.
News Comparison of Safety and Efficacy of Oral and Intravenous Administration of Combination NEPA in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting
Both oral and intravenous administration of a combination of netupitant (a neurokinin 1 receptor antagonist − NK1RA) with palonosetron (a 5-HT3 receptor antagonist) offer prevention of chemotherapy-induced nausea and vomiting (CINV) for up to 5 days after its administration. Although the i.v. form of netupitant (fosnetupitant) + palonosetron (NEPA) did not lead to injection site reactions or anaphylactic reactions in a Phase III study, hypersensitivity and anaphylactic reactions have been described with other i.v. administered NK1RAs. Thus, the aim of the study recently published in the journal The Oncologist was to evaluate the safety and efficacy of i.v. NEPA in women with breast cancer treated with anthracycline and cyclophosphamide-containing chemotherapy.
News Trifluridine/tipiracil, regorafenib, or supportive therapy? Factors affecting the success of mCRC treatment
Currently, there are no biomarkers available to help decide, for a specific patient with refractory metastatic colorectal cancer (mCRC), whether therapy with trifluridine/tipiracil or regorafenib will be more effective and which patients will benefit the most from the treatment. A group of Czech oncologists presented the results of their analysis on this topic at the Gastrointestinal Symposium of the American Society of Clinical Oncology (ASCO) held in January 2020 in San Francisco.
News Physical Activity in Hemophiliacs and How to Ensure it Safely
Physical activity is beneficial − and this holds true for patients with hemophilia as well. New therapeutic modalities offer additional possibilities to optimize prevention so that, among other things, it allows hemophiliacs to engage in sports.
News Which Anticoagulant Treatment Do Patients Prefer?
For patients with atrial fibrillation (AF) for whom anticoagulant therapy is indicated for stroke prevention, good adherence to treatment is crucial. A recent study evaluated their perception of dabigatran treatment in comparison with vitamin K antagonists.
News Cardiovascular Benefit of SGLT2 Inhibitors Confirmed
The cardiovascular (CV) benefit of SGLT2 inhibitors in type 2 diabetics, demonstrated by empagliflozin in the EMPA-REG OUTCOME study, has also been confirmed by studies with canagliflozin (CANVAS), a new analysis of the CVD REAL study involving empagliflozin, canagliflozin, and dapagliflozin, as well as individual sub-studies of the EMPA-REG OUTCOME study. These findings, presented in June 2017 at the American Diabetes Association (ADA) congress, are summarized in a recently published article in the journal Critical Pathways in Cardiology.
News Favorable effect of linagliptin on renal endothelial functions in patients with type 2 diabetes mellitus
Diabetic nephropathy is the cause of up to 50% of cases of end-stage chronic kidney disease. The main pathological mechanism involved in the development of the early stage of diabetic nephropathy is endothelial dysfunction. The aim of the German study was to evaluate the effects of linagliptin on endothelial function in the renal vasculature.
News Impact of Empagliflozin on the Risk of Cardiovascular Death and Need for Hospitalization Due to Heart Failure
In the EMPA-REG OUTCOME study, empagliflozin reduced the risk of cardiovascular death and the number of hospitalizations due to heart failure in patients with type 2 diabetes (T2DM) who had confirmed cardiovascular disease at study entry. In the following analysis, the authors focused on the benefit of empagliflozin in patients with different levels of risk for heart failure development.